Aquestive Therapeutics Faces Securities Fraud Lawsuit with Lead Plaintiff Deadline

Aquestive Therapeutics, Inc. (NASDAQ: AQST) is facing a securities fraud class action lawsuit, with a lead plaintiff deadline set for May 4, 2026. Investors who purchased securities between June 16, 2025, and January 8, 2026, may be eligible for compensation through a contingency fee arrangement. The Rosen Law Firm is representing the plaintiffs in the case.

By THE ROSEN LAW FIRM, P. A. · PR Newswire · April 22, 2026, 05:37 UTC

Tickers: $AQST

Topics: Aquestive Therapeutics class action investor rights Rosen Law Firm securities litigation

Read the full article at PR Newswire

More World news

Allstate Announces Quarterly Dividend of $1.08 Per Share PR Newswire · November 12, 2026, 17:38 UTC
Stephanie Link Shifts AI Allocation from Nvidia to Micron Technology Following CEO Resignation CNBC · November 12, 2026, 17:37 UTC
Boyd Group Reports 28% Revenue Growth and $90 Million in Cost Savings for Q3 2026 Motley Fool · November 12, 2026, 17:33 UTC
Hugging Face CEO Reaffirms Commitment to Open-Source AI Following Nvidia CEO Jensen Huang's Departure TechCrunch · November 12, 2026, 17:36 UTC
Marimed Reports Record $44.2M Quarterly Revenue and Targets 2027 New York Launch Seeking Alpha · November 12, 2026, 17:30 UTC
Nebius Group Reports Massive Q3 2026 Revenue Growth Driven by AI Cloud Expansion Motley Fool · November 12, 2026, 17:29 UTC
Reagan Institute Launches Society of Fellows to Support Early Career Scholars PR Newswire · November 12, 2026, 17:32 UTC
Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC